2018
DOI: 10.1016/j.atherosclerosis.2018.06.724
|View full text |Cite
|
Sign up to set email alerts
|

Lipid-lowering efficacy of proprotein convertase subtilisin kexin 9 inhibitors (iPCSK9) in the interdosis period. A descriptive study

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles